|Bid||184.67 x 1000|
|Ask||186.95 x 800|
|Day's Range||171.55 - 185.46|
|52 Week Range||47.50 - 185.52|
|Beta (3Y Monthly)||2.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||210.75|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
Reata Pharmaceuticals and Axsome Therapeutics each have had a terrific 2019, which helps offset the losing bets in this high-beta sector of the market.
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
Reata Pharmaceuticals soared early Tuesday on positive Phase 2 test results of a treatment for Friedreich's ataxia. The biotech recently reacquired omaveloxolone from AbbVie.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Synthesis Energy Systems (NASDAQ: SES ) shares ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
Reata Pharmaceuticals Inc. shares surged after hours Monday as the biotech company announced positive results from a clinical trial for a neuromuscular disorder treatment. Reata shares, which had been halted after hours, surged 33% in the extended session, after closing up 5% at $100.59 in Monday trading for a market cap of just over $3 billion. Compared to placebo, the company said a mid-stage study of its treatment omaveloxolone significantly improved symptoms of Friedreich's ataxia, a debilitating neuromuscular disease that results in loss of coordination, weakness and fatigue. There are currently no treatments approved by the Food and Drug Administration for the disease, which affects about 22,000 globally, the company said.
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR.
IRVING, Texas, Oct. 11, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting.
Reata Pharmaceuticals stock jumped Thursday after the biotech company reacquired the rights to several important drugs from pharmaceutical giant AbbVie. Two drugs are in pivotal studies.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie, Inc. (AbbVie) for territories outside of the United States with respect to bardoxolone methyl (bardoxolone) and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators. As a result, Reata now possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone methyl (bardoxolone), omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin Co., Ltd.
Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Manmeet S. Soni as Chief Financial Officer (CFO) and Executive Vice President, effective August 28, 2019. Mr. Soni will report to Reata’s Chief Executive Officer and President, Warren Huff, and will provide strategic leadership in the overall financial management of Reata. His responsibilities will include corporate finance and accounting, information technology, corporate strategy, corporate communications, and investor relations. Jason D. Wilson, who has been with Reata since 2006 and served as CFO, will assume a new role as Executive Vice President of Operations. Mr. Wilson will continue to report to the Chief Executive Officer and will oversee Reata’s operations, including program and clinical operations, manufacturing, bioinformatics, quality, global alliances, and human resources.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.79% and 0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas, Aug. 08, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter.
In 2002 J. Huff was appointed CEO of Reata Pharmaceuticals, Inc. (NASDAQ:RETA). This analysis aims first to contrast...